BioWorld Asia

April 16, 2003

Celltech Poised To Acquire OGS After Other Parties Drop Interest

LONDON - Oxford GlycoSciences plc succumbed to the hostile bid from Celltech plc that will lead to the breakup of the business, after failing to attract any better offers. (BioWorld International) Read More

Oxxon Completes £15M Round To Fund Therapeutic Vaccines

Engineered Lymphocytes Show Promise In Metastatic Cancer

Karo Bio Plans To Net SEK120M From Discounted Rights Issue

Affitech, NatImmune Team Up In Colon Cancer Collaboration

Entomed, Achillion Enter Deal For Antiviral Drug Discovery

European Parliament Moves For Strict Cell, Tissue Rules

EU Consumer Commissioner Favors Progress In Biotech

IDM Acquires Cancer Assets For Stock In Deal With Jenner

Proteome Sciences, IDEXX Enter Deal To Develop BSE Diagnostic

MedPharma Looking To Go Public To Fund Sexual Dysfunction Drugs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 30, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026